Rituximab biosimilar - Biocad

Drug Profile

Rituximab biosimilar - Biocad

Alternative Names: AcellBia; Acellbia; BCD-020; USMAL

Latest Information Update: 06 Jul 2017

Price : $50

At a glance

  • Originator Biocad
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Preregistration Rheumatoid arthritis

Most Recent Events

  • 04 Jul 2017 Preregistration for Non-Hodgkin's lymphoma in India (IV)
  • 04 Jul 2017 Preregistration for Rheumatoid arthritis in India (IV)
  • 04 Jul 2017 CDSCO recommends approval of rituximab biosimilar for Rheumatoid arthritis and non-Hodgkin's lymphoma in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top